Arbutus Biopharma Corporation ABUS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $23.71M+31.6% | $18.01M-19.6% | $22.41M-40.1% | $37.41M+0.9% | $37.08M+2.1% | ||
| $71.52M-2.6% | $73.46M+3.0% | $71.29M+17.5% | $60.68M-19.8% | $75.63M-12.4% | ||
| $178.74M— | $0-100% | $905K-11.7% | $1.03M-13.3% | $1.18M-50.9% | ||
| $1.73M+12.6% | $1.54M-45.7% | $2.84M-29.2% | $4.01M+37.2% | $2.92M+27.8% | ||
| $300K0.0% | $300K0.0% | $300K+200% | $100K-50.0% | $200K-33.3% | ||
| $277.01M+193% | $94.46M-3.1% | $97.44M-5.5% | $103.12M-11.7% | $116.81M-8.3% | ||
| $22K-31.3% | $32K-76.6% | $137K-7.4% | $148K-11.9% | $168K-94.9% | ||
| $224K+5.2% | $213K-98.4% | $13.35M+0.2% | $13.32M-0.1% | $13.33M+2.5% | ||
| $131K+0.8% | $130K-0.8% | $131K— | $0-100% | $34K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $277.16M+193% | $94.62M-3.2% | $97.71M-5.4% | $103.27M-11.7% | $117.01M-11.2% | ||
| $1.46M+24.6% | $1.17M+16.0% | $1.01M-23.5% | $1.32M-41.0% | $2.24M-3.3% | ||
| $631K+15.4% | $547K+3.0% | $531K+3.3% | $514K-8.7% | $563K+16.6% | ||
| $5.11M-15.0% | $6.01M+15.9% | $5.18M+3.2% | $5.02M-74.2% | $19.43M+24.4% | ||
| $0— | —— | $0— | $0— | $0— | ||
| $0-100% | $199K-49.1% | $391K-32.0% | $575K-8.1% | $626K-22.3% | ||
| $16.99M-5.8% | $18.04M-11.2% | $20.31M+0.1% | $20.29M-46.4% | $37.85M+10.2% | ||
| $1.44B+1.6% | $1.42B+0.2% | $1.42B+0.1% | $1.42B+0.1% | $1.42B+0.4% | ||
| $74.26M-10.9% | $83.32M0.0% | $83.29M+0.8% | $82.63M+0.7% | $82.09M0.0% | ||
| -$1.21B+12.3% | -$1.38B-0.3% | -$1.38B-0.6% | -$1.37B+0.2% | -$1.37B-1.8% | ||
| -$48.2M-0.2% | -$48.1M+0.1% | -$48.13M+0.1% | -$48.19M0.0% | -$48.17M-0.1% | ||
| $260.18M+240% | $76.58M-1.1% | $77.4M-6.7% | $82.98M+4.8% | $79.16M-18.7% | ||
| $277.16M+193% | $94.62M-3.2% | $97.71M-5.4% | $103.27M-11.7% | $117.01M-11.2% | ||
| $71.53M-2.5% | $73.38M+3.0% | $71.24M+17.4% | $60.68M-19.7% | $75.61M-12.3% | ||
| $71.52M-2.6% | $73.46M+3.0% | $71.29M+17.5% | $60.68M-19.8% | $75.63M-12.4% | ||
| $71.52M-2.6% | $73.46M+3.0% | $71.29M+17.5% | $60.68M-19.8% | $75.63M-12.4% | ||
| $131K+0.8% | $130K-0.8% | $131K— | $0-100% | $34K0.0% | ||
| $71.53M-2.5% | $73.38M+3.0% | $71.24M+17.4% | $60.68M-19.7% | $75.61M-12.3% | ||
| $95.2M— | —— | $93.7M-4.5% | $98.1M-13.0% | $112.7M— | ||
| $131K+0.8% | $130K-0.8% | $131K— | $0-100% | $34K0.0% | ||
| $131K+0.8% | $130K-0.8% | $131K— | $0-100% | $34K0.0% | ||
| $4.47M-18.0% | $5.46M+17.3% | $4.65M+3.2% | $4.51M-62.8% | $12.11M+60.1% | ||
| $1.57M+46.1% | $1.08M+143% | $443K+25.9% | $352K-84.3% | $2.24M+92.2% | ||
| $245K-61.7% | $640K-16.1% | $763K-0.7% | $768K-87.1% | $5.97M— | ||
| $8.6M+2.5% | $8.4M-24.0% | $11.05M+2.5% | $10.78M+2.5% | $10.52M+2.9% | ||
| $631K-15.4% | $746K-19.1% | $922K-15.3% | $1.09M-8.4% | $1.19M-7.8% | ||
| 196.9M+2.3% | 192.5M+0.3% | 192M+0.2% | 191.6M+0.1% | 191.5M+0.8% | ||
| 1.2M— | —— | 1.2M0.0% | 1.2M0.0% | 1.2M— | ||
| $1.44B+1.6% | $1.42B+0.2% | $1.42B+0.1% | $1.42B+0.1% | $1.42B+0.4% | ||
| $13K-85.1% | $87K+42.6% | $61K+578% | $9K-64.0% | $25K-55.4% | ||
| $23K— | $0-100% | $4K-63.6% | $11K+120% | $5K-16.7% | ||
| 22— | 0-100% | 8-60.0% | 20+42.9% | 14+133% | ||
| $71.53M-2.5% | $73.38M+3.0% | $71.24M+17.4% | $60.68M-19.7% | $75.61M-12.3% | ||
| $789K-63.5% | $2.16M+6.7% | $2.02M+107% | $975K+97.4% | $494K-85.4% | ||
| $1.57M+46.1% | $1.08M+143% | $443K+25.9% | $352K-84.3% | $2.24M+92.2% | ||
| $407K-1.2% | $412K-0.2% | $413K-62.2% | $1.09M-6.9% | $1.17M+69.8% | ||
| $23K— | $0-100% | $4K-63.6% | $11K+120% | $5K-16.7% | ||
| $13K-85.1% | $87K+42.6% | $61K+578% | $9K-64.0% | $25K-55.4% | ||
| $71.53M-2.5% | $73.38M+3.0% | $71.24M+17.4% | $60.68M-19.7% | $75.61M-12.3% | ||
| $71.52M-2.6% | $73.46M+3.0% | $71.29M+17.5% | $60.68M-19.8% | $75.63M-12.4% | ||
| $14.49M+41.8% | $10.22M+30.4% | $7.84M-74.2% | $30.4M+15.3% | $26.38M-10.7% | ||
| $196.95M+2.3% | $192.53M+0.3% | $191.95M+0.2% | $191.64M+0.1% | $191.48M+0.8% | ||
| $196.95M+2.3% | $192.53M+0.3% | $191.95M+0.2% | $191.64M+0.1% | $191.48M+0.8% | ||
| $22— | $0-100% | $8-60.0% | $20+42.9% | $14+133% | ||
| $0— | —— | $0— | $0— | $0— | ||
| $3.28M-4.8% | $3.44M-6.6% | $3.68M-5.8% | $3.91M-11.3% | $4.41M-8.7% | ||
| $1.16M— | —— | $1.16M0.0% | $1.16M0.0% | $1.16M— | ||
| $245K-61.7% | $640K-16.1% | $763K-0.7% | $768K-87.1% | $5.97M— | ||
| 2— | —— | 20.0% | 20.0% | 2— | ||
| 1— | —— | 10.0% | 10.0% | 1— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arbutus Biopharma Corporation's total assets?
- Arbutus Biopharma Corporation (ABUS) holds $277.2M in total assets, up 136.9% year over year.
- How much debt does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation carries $631.0K in total debt against $260.2M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation holds $23.7M in cash and equivalents.
- Can Arbutus Biopharma Corporation cover its short-term obligations?
- Its current ratio is 54.26 — current assets exceed current liabilities.
- Where does Arbutus Biopharma Corporation's balance sheet data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
